Key result
Early immunosuppression dictates outcomes in giant cell myocarditis, complicated by cardiogenic shock in ~64% of cases.
Why the study?
Giant cell myocarditis has an incompletely understood immune pathogenesis and a frequently fulminant course requiring rapid intervention for diagnosis and often life-saving immunosuppressive therapy.
Does early diagnosis and immunosuppressive therapy improve outcomes in patients with giant cell myocarditis?
Population
25 patients diagnosed with giant cell myocarditis between March 2019 and May 2025
Design
Systematic review of observational studies and case reports
Authors
Loading...
Warrants prompt biopsy and immunosuppression on suspicion of giant cell myocarditis; reinforces evidence for timely intervention in this fulminant disease.**[[1]](https://www.mdpi.
Does early diagnosis and immunosuppressive therapy improve outcomes in patients with giant cell myocarditis?
Early diagnosis and prompt administration of immunosuppressive therapy are critical to improving outcomes in giant cell myocarditis, which otherwise has a fulminant and often fatal course.
Kundnani et al. (2026) studied this question. Giant cell myocarditis resulted in cardiogenic shock in 64% of cases, death in 16%, and heart transplantation in 16%, with patient outcomes primarily dependent on early immunosuppressive therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: